Stocks · Healthcare · Biotechnology
Recursion Pharmaceuticals, Inc. RXRX
$4.12 +1.23% Close, Oct 2, 2026 · NASDAQ · Market cap $2.16B
High risk
Next earnings report: Nov 4, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin widened to -991.7% from -1008.2% a year earlier.
- The diluted share count rose 27.6% in a year.
- Revenue over the last four quarters was $54.9M, down 14.9% from a year earlier, slowing from 11.0% a quarter earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
Growth21Very weak
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 17%
- Revenue growth, 3-year CAGRTop 27%
- Revenue growth accelerationBottom 11%
Quality10Very weak
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 27%
- Gross marginBottom 6%
- Operating marginBottom 12%
- Accruals (lower is better)Top 24%
- Interest coverBottom 9%
Value21Very weak
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 28%
- Free-cash-flow yieldBottom 28%
- EBITDA / enterprise valueBottom 24%
- Sales / enterprise valueBottom 16%
Momentum45Neutral
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 14%
- 6-month returnTop 30%
- 1-year return vs S&P 500Bottom 29%
- Distance from 52-week highBottom 38%
- Trend checklist (0–4)Top 20%
Revisions11Very weak
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 33%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyBottom 8%
- Upside to consensus price targetBottom 34%
Stability8Very weak
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 23%
- Maximum drawdown, 3 yearsBottom 29%
- Beta vs S&P 500 (lower is better)Bottom 2%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 11.0% | -14.9% | ↓ |
| Gross margin | -3.8% | -46.7% | ↓ |
| Operating margin | -1008.2% | -991.7% | ↑ |
| FCF margin | -611.8% | -645.8% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -14.9% | 11.0% | ↓ | Bottom 17% |
| Gross margin | -46.7% | -3.8% | ↓ | Bottom 6% |
| Operating margin | -991.7% | -1008.2% | ↑ | Bottom 12% |
| Net margin | -945.9% | -1007.1% | ↑ | — |
| Free-cash-flow margin | -645.8% | -611.8% | ↓ | — |
| Return on invested capital | -48.3% | — | Bottom 27% | |
| Revenue growth, 3-year CAGR | 23.5% | — | Top 27% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -13.9%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 165.4%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -18.5 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -364.6×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -17.97%
- Shareholder yield
- -17.97%
- Share count change, 1 year
- +27.6%
- Share count change, 3-year CAGR
- +38.3%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 5, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 3 of 8
- Average EPS surprise, last 4
- +13.2%
- Average 2-day reaction, last 8
- -2.2%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $5.30
- Target vs current price
- +28.6%
- Analysts with a rating
- 10
- Share rating Buy or Strong Buy
- 40%
- Consensus rating
- Hold
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 5, 2026 | -4.2% | -4.2% | +1.2% | +0.6% | — |
| May 6, 2026 | +26.7% | +1.8% | -6.5% | +3.0% | -11.0% |
| Feb 25, 2026 | +25.0% | +6.8% | +0.3% | -10.2% | -16.1% |
| Nov 5, 2025 | +5.3% | -0.8% | -5.8% | -6.8% | -16.4% |
| Aug 5, 2025 | -17.1% | -4.7% | -8.8% | -19.7% | +1.9% |
| May 5, 2025 | -13.6% | -16.5% | -24.0% | -23.3% | +1.9% |
| Feb 28, 2025 | -20.5% | -2.1% | -18.6% | -22.2% | -46.8% |
| Nov 6, 2024 | -3.0% | +2.2% | +11.1% | +4.5% | +11.6% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | -$0.25 | -$0.24 | -4.2% | $7.3M |
| May 6, 2026 | -$0.22 | -$0.30 | +26.7% | $6.3M |
| Feb 25, 2026 | -$0.21 | -$0.28 | +25.0% | $35.4M |
| Nov 5, 2025 | -$0.36 | -$0.38 | +5.3% | $5.2M |
| Aug 5, 2025 | -$0.41 | -$0.35 | -17.1% | $19.1M |
| May 5, 2025 | -$0.50 | -$0.44 | -13.6% | $14.7M |
| Feb 28, 2025 | -$0.53 | -$0.44 | -20.5% | $4.5M |
| Nov 6, 2024 | -$0.34 | -$0.33 | -3.0% | $26.1M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 30.59× | — | — | Bottom 16% |
| Free-cash-flow yield | -16.39% | — | — | Bottom 28% |
| Earnings yield | -25.24% | — | — | Bottom 28% |
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✗ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 12
- Days above the 200-day average
- 11
- 50-day average slope (20 days)
- +2.9%
- 200-day average slope (20 days)
- -2.1%
- Distance from 50-day average
- +20.5%
- Distance from 200-day average
- +15.3%
- RSI (14)
- 61.9
- Relative volume
- 0.89×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 74.4%
- Volatility vs own 5-year history
- 31th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 3.09
- Correlation with S&P 500
- 0.56
- Current drawdown from 1-year high
- -39.3%
- Maximum drawdown, 3 years
- -81.7%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Jul 13, 2021 | Mar 30, 2026 | -93.1% | 1183 days | Not yet recovered |
| Apr 29, 2021 | May 13, 2021 | -38.1% | 10 days | 24 days (Jun 17, 2021) |
| Apr 16, 2021 | Apr 19, 2021 | -10.5% | 1 days | 2 days (Apr 21, 2021) |
| Jun 21, 2021 | Jun 23, 2021 | -10.4% | 2 days | 8 days (Jul 6, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $2.16B
- EPS, diluted (TTM)
- -$1.04
- Revenue (TTM)
- $54.9M
- 52-week range
- $2.77 – $7.18
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $10.0M | $39.7M | $43.9M | $58.8M | $74.7M |
| Gross profit | $10.0M | -$8.6M | $1.3M | $13.6M | -$46.3M |
| Operating income | -$182.8M | -$245.7M | -$350.1M | -$479.0M | -$648.1M |
| Net income | -$186.5M | -$239.5M | -$328.1M | -$463.7M | -$644.8M |
| EPS (diluted) | -$1.05 | -$1.36 | -$1.58 | -$1.69 | -$1.44 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $26.1M | $4.5M | $14.7M | $19.1M | $5.2M | $35.5M | $6.5M | $7.7M |
| Net income | -$95.7M | -$178.9M | -$202.5M | -$171.9M | -$162.3M | -$108.1M | -$117.5M | -$131.0M |
| EPS (diluted) | -$0.34 | -$0.53 | -$0.50 | -$0.41 | -$0.36 | -$0.21 | -$0.22 | -$0.25 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$158.6M | -$83.5M | -$287.8M | -$359.2M | -$371.8M |
| Capital expenditure | -$39.8M | -$37.4M | -$12.0M | -$13.7M | -$6.5M |
| Free cash flow | -$198.4M | -$120.9M | -$300.3M | -$372.9M | -$378.3M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $462.9M | $143.7M | $128.1M | $300.4M | $533.0M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $545.7M
- Total assets
- $1.21B
- Total liabilities
- $297.7M
- Total debt
- $61.9M
- Net debt
- -$483.8M
- Shareholders’ equity
- $915.0M
As of Jun 30, 2026 (filed Aug 5, 2026).
Short interest
- Shares sold short
- 178,724,433
- Days to cover
- 12.56
- Change vs previous report
- -0.2%
FINRA short interest, settlement date Sep 15, 2026.